Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Timothy Lewis Cannon, Michael Rothe, Elizabeth Garrett-Mayer, Andrew Gregory, Meredith McKean, Kunal C. Kadakia, Evan P. Pisick, Bamidele Adesunloye, Jasdeepa Nagi, Erwin Grussie, Carmen Julia Calfa, Majd Chahin, Jaykumar Ranchodbhai Thumar, Stanley Madu Nwabudike, Gahyun Gim, Abigail Gregory, Dominique C. Hinshaw, Gina N. Grantham, Susan Halabi, Richard L. Schilsky
Institutions: Inova Fairfax Hospital, American Society of Clinical Oncology, Aurora Health Care, Sarah Cannon, Levine Cancer Institute, Wake Forest University, City of Hope, Angeles Clinic and Research Institute, University of Miami, Sylvester Comprehensive Cancer Center, Hartford Hospital, University of Florida Health, Duke Medical Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162488927
Cites:
Cited by:
Related to: